Publications & Posters

All categories

Publications

Posters

All Cell Engagers

AFM11

AFM13

AFM24

AFM26

All years

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

Construction and Characterization of Novel CD33/CD3 Tandem Diabodies (TandAbs®) for the Treatment of Acute Myeloid Leukemia (AML)

Reusch et al.
ASCO 2015

TandAbs: potent and well-manufacturable bi-specific antibodies

Weichel et al.
European Pharmaceutical Review 2015 20(1): 27-32

link to publication

Specific NK cell activation to treat relapsed/refractory (r/r) Hodgkin Lymphoma (HL) patients – final, updated data on clinical outcome, pharmacokinetics and pharmacodynamics of a phase 1 study investigating AFM13, a bispecific anti- CD30/CD16A TandAb

Rothe et al.
ASH 2014

A CD19/CD3 bispecific TandAb, AFM11, recruits T cells to potently and safely kill CD19+ tumor cells in pre-clinical models

Reusch et al.
PEGS 2014

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.

Reusch et al.
MAbs. 2014 Mar 26;6(3).

link to publication

Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients

Reiners et al.
Mol Ther. 2013 Apr;21(4):895-903. doi: 10.1038/mt.2013.14. Epub 2013 Mar 5./.

link to publication

T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16

Pörtner et al.
Cancer Immunol Immunother. 2012 Oct;61(10):1869-75

link to publication

RECRUIT-TandAbs: harnessing the immune system to kill cancer cells

McAleese F, Eser M.
Future Oncol. 2012 Jun;8(6):687-95.

link to publication

Recombinant Antibodies for Immunotherapy

Authors: Le Gall F and Little M., Editor: Melvyn Little
Publ. Cambridge University Press, 2009

link to publication

1
2
3
4
5

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.